icad — Merger or Acquisition (April 2025)
18 slides from icad's merger presentation, Apr 29, 2025
Slide 1: iCAD Town Hall
Creating a world where _ Cancer _Can’t Hide. iCAD Town Hall April 29,2025
Slide 2: No Offer or Solicitation
No Offer or Solicitation This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or s
Slide 3: Forward-Looking Statements
Forward-Looking Statements This communication contains certain “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1984, as amen
Slide 4: Agenda
++ iCAD Agenda 1. WELCOME - Dana 2. SPECIAL GUESTS -- DeepHealth 3. RECAP: PHASES AND TIMELINE - Dana 4, REMINDER: COMMUNICATION PROTOCOL - Dana 5. RECAP: WHAT’S NEXT - Dana 6. WORD ON THE STREET -- Michelle 7. SBI 2025 IN REVIEW - Jeremy 8. STAFF RECOGNITION - Brian 9. Q&A
Slide 5: Special guests: DeepHealth leaders
= Sanjog Misra, Chief Commercial Officer = Sham Sokka, PhD., Chief Operating and Technology Officer
Slide 6: RadNet - A national leader in diagnostic imaging services and digital health solutions
RadNet - A national leader in diagnostic imaging services and digital health solutions GR 3 9 8 Imaging Centers Largest owner and operator of outpatient imaging centers inthe US. Annual chest CT exams 300 A national lung screening leader 2 Joint Ventures Health System Joint Ventures across the count
Slide 7: Global leader in AI-powered health informatics
Global leader in Al-powered health informatics (@ RadNet's Digital Health segment Europe 0 0 United States Middle East 6 400+ —=— Sts ine Customers worldwide* india @ 2% Global footprint ei with local clinical expertise & Diverse Large data sets enable development, validation, sana _@ patient data a
Slide 8: Our unique capabilities
Our unique capabilities oe Vertically integrated Rapid iteration, validation and Craatir prototyping Clinical Al solutions in breast, lung, prostate, and brain health High innovation speed and time to market .. Clinically proven Clinical sites 800+ = and3,000+ radiologists Demonstrated (= Clinical i
Slide 9: Acquisition expected to create attractive potential synergies
Acquisition expected to create attractive potential synergies Cost synergies Commercial synergies Product synergies $7M+ run rate cost synergies identified: ~S4M direct savings, e.g., board of directors, public company costs, audits, etc. ~$3M by fulfilling pre-existing hiring plans of DeepHealth De
Slide 10: Most comprehensive Breast AI Portfolio
Most comprehensive Breast Al Portfolio From Al only to complete technology stack for Enhanced Screening Clinical Impact Workflow Efficiency Revenue Generation Value anit vane — S Ls ‘ eo Al Ee - Pa SPL. " : Safeguard Alwith Integrated viewing Review and reporting Al Detection + Workflow Efficiency +
Slide 11: Portfolio of solutions
Portfolio of solutions Improving operational efficiency, clinical excellence, and the delivery of care deephealth Enterprise Imaging Population Health © Profound & © everson suite te @ Diasnostic Suite™ @ Prostate @ Techtive™ @ Brain DeepHealth RIS/PACS Lun ) Clinical ® J Collaboration & Follow-up ‘
Slide 12: Recap: Phases and Timeframes
+ iCAD Recap: Phases and Timeframes Phase 1- Sign - Began April 15 Between Phase 1 and 2: Workstreams + Refine anticipated Revenue and cost synergies + People meet People * Big picture Product Roadmap synergies Phase 2 - Close (late 2Q/3Q) « Announcements by iCAD and DeepHealth in parallel - iCAD em
Slide 13: Reminder: Communications Protocol
4: iCAD Reminder: Communications Protocol Until the deal is closed, iCAD and DeepHealth cannot and will not reach out or communicate with each other's employees, customers, or partners. All forms of communications related to the potential merger need to be aligned with: Michelle Strong, COO, mstrong
Slide 14: Recap: What's Next
+ iCAD Recap: What’s Next What Can You Do? « Hit your Milestones and Deliverables for Q2! + Bubble up questions and concerns + Don't be afraid if there isn't a steady stream of “merger news”...both companies enter into a quiet period until we reach Phase 2: Close « Uphold the communications protocol
Slide 15: Cancer Can't Hide.
Cancer Can’t Hide. oh By 2025 APRIL 24-27
Slide 16: SBI 2025
SBI 2025 SOCIETY OF BREAST IMAGING SYMPOSIUM §¢ Colorado Springs, CO | 5 April 24-27 1600+ Attendees | 77 Exhibitors | Rapidly Growing Al Focus iCAD by the Numbers «102: 104 40 8 Booth Engagements (+9 YoY) Customer Event Attendees (47 Pre-Registrants) Partner Meetings (e.g. GE, Koios, Ramsoft) Marke
Slide 17: New Hires - Welcome to iCAD!
New Hires - Welcome to iCAD! Mark Koeniguer, Chief Commercial Officer v Priv
Slide 18: No Offer or Solicitation
No Offer or Solicitation This communication does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval, nor shall there be any sale, issuance or transfer of securities in any jurisdiction in which such offer, solicitation or s